Beijing Aosaikang Pharmaceutical Co., Ltd.

Company Profile

1、Outstanding R&D Capability Accelerates the Realization of Innovation Value BEIJING AOSAIKANG PHARMACEUTICAL CO.,LTD. originated from Nanjing Haiguang Applied Chemistry Research Institute, the first non-public drug research institute in Jiangsu Province. The company has now independently established two major R&D platforms for chemical and biological drugs. It possesses key R&D technologies and industrialization capabilities in chiral drugs, targeted drugs, and high-end formulations. A comprehensive R&D system driven by both chemical and biological drugs has been built. The company employs six national key talents and seven provincial key talents. Two core technologies have won the China Patent Gold Award and the Jiangsu Province Patent Project Gold Award, respectively. Three core patent technologies have successively received the Jiangsu Province Patent Project Excellence Award. In terms of new product approvals, from 2024 to the present, the company has obtained marketing authorization for nine new products, including the Class 1 innovative drug Lertinib Tablets, Dexlansoprazole for Injection, Eltrombopag Olamine Tablets, Isavuconazonium Sulfate for Injection, Trifluridine and Tipiracil Tablets, Neratinib Maleate Tablets, Toremifene Citrate Tablets, Fosaprepitant Dimeglumine for injection, and the co-introduced product Dapagliflozin and Metformin Hydrochloride Sustained-release Tablets. Regarding active pharmaceutical ingredient (API) approvals, from 2024 to the present, the company has obtained marketing authorization for nine APIs, including Lertinib, Eltrombopag Olamine, Isavuconazonium sulfate, Dexlansoprazole, Neratinib Maleate, Trifluridine, Tipiracil Hydrochloride, and Avatrombopag Maleate. This further strengthens the company's integrated competitiveness of characteristic APIs and formulations, and enhances its cost advantages and overall operational efficiency. The company focuses on the development of innovative drugs and high-barrier complex formulations. It drives innovation through both independent R&D and collaborative introductions, with a particular emphasis on the R&D of small-molecule targeted innovative drugs and tumor immunotherapy biological innovative drugs. The company currently has a total of 42 main ongoing R&D projects. Among them, 10 key chemical and biological innovative drugs, which have been disclosed, have made significant progress in 2024. Additionally, several innovative drugs are in the preclinical research stage. 2、Forming an Anti-Infection Product Portfolio to Build New Competitive Advantages Adhering to the R&D guiding principle of “patient needs at the core and clinical value as the orientation,” the company not only continues to focus on the long-term layout in the fields of digestion and anti-tumor treatment, but also pays particular attention to the anti-infection field, which is closely related to the health of the population and poses a significant threat to public health security. Currently, the issue of antimicrobial resistance is becoming increasingly severe. Starting from the perspective of clinical needs, the company has already laid out and continuously expanded a unique portfolio of products targeting resistant bacterial infections. 3、Establishing the Quality Management Objective of “Developing New-Form Productivity to Boost Quality Internationalization” The company adheres to the quality policy of “Quality is the foundation for corporate survival” and is committed to applying advanced management tools and concepts to enhance its quality management level. During the process of improving quality management, the company has developed a unique quality management model. In line with the cGMP model for quality management systems, the company has established a quality management system for the entire life cycle of pharmaceutical products. In 2024, the company set the quality management objective of “Developing New-Form Productivity to Boost Quality Internationalization.” This objective aims to adapt to the new situation brought about by the new round of technological revolution and industrial transformation, to promote the development of existing productivity, and to elevate the quality management level to an internationally advanced standard. It also makes a scientific layout for the company’s future quality development. 4、Mature brand and channel development, Professional Evidence-Based Medicine Promotion Capability In recent years, the market environment of the pharmaceutical industry has undergone profound changes. In response to this situation, the company has actively adjusted its sales strategies and proactively adapted to market changes. Leveraging its mature brand and channel advantages, the company has focused on clinical value and academic promotion, and developed differentiated sales strategies based on product characteristics. This has led to the formation of a multi-channel sales system with effective coverage. In terms of evidence-based medicine promotion, the company has focused on the anti-infection field and actively participated in numerous academic conferences related to infection, critical care, hematology, and respiratory medicine. The company has been instrumental in disseminating the latest medical information and treatment protocols from these conferences to front-line clinical settings and grassroots departments. By collaborating with doctors to learn about the latest developments in treatment fields and clinical research, the company has effectively promoted the implementation of rational and precise medication plans in the anti-infection field, as well as the widespread application of advanced diagnostic and treatment experiences. 5、Talent-Driven: Building Industry-Leading Talent Development and Incentive Mechanisms The company unwaveringly regards “talent-driven” as the core engine for corporate development. It is committed to building and continuously optimizing industry-leading talent development and incentive mechanisms to unleash the potential and intrinsic growth of talents, thereby achieving a competitive edge in talent. The company has established a multi-dimensional and comprehensive talent development mechanism to empower employees' growth throughout their entire career lifecycle. In the two core areas of R&D and quality management, dual career pathways are provided to unlock the potential of talents. By closely monitoring industry trends and aligning with the company's development needs, dynamic talent management strategies are implemented. Adhering to the corporate vision of “Creating a Happy Aosaikang,” the company has built an employee incentive system that encourages value creation and shared success.